0.2173

6.58% -0.0153

After Hours: .22 0.0027 +1.24%

Theriva Biologics Inc (TOVX)

Overview News Price History Discussions Forecast

Theriva Biologics Inc stock is traded at $0.2173, with a volume of 1.82M. It is down -6.58% in the last 24 hours and down -27.08% over the past month. Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Previous Close:

$0.2326

Open:

$0.231

24h Volume:

1.82M

Relative Volume:

0.13

Market Cap:

$7.33M

Revenue:

Net Income/Loss:

$-18.35M

P/E Ratio:

-0.1873

EPS:

-1.16

Net Cash Flow:

$-19.20M

1W Performance:

-3.64%

1M Performance:

-27.08%

6M Performance:

-56.51%

1Y Performance:

-81.74%

1-Day Range:

$0.215

$0.2338

1-Week Range:

$0.21

$0.2359

52-Week Range:

$0.198

$2.08

Theriva Biologics Inc Stock (TOVX) Company Profile

Name

Theriva Biologics Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

301 417 4364

Address

9605 Medical Center Drive, Suite 270, Rockville

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

TOVX's Discussions on Twitter

Compare TOVX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TOVX Theriva Biologics Inc	0.2173	7.85M	0	-18.35M	-19.20M	-1.16
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Theriva Biologics Inc Stock (TOVX) Latest News

Dec 05, 2025

Why Theriva Biologics Inc. stock is a strong buy call2025 Analyst Calls & AI Driven Stock Reports - Newser

Dec 05, 2025

Can Theriva Biologics Inc. (SFY0) stock test all time highs2025 Market Overview & Verified Swing Trading Watchlists - Newser

Dec 05, 2025

Dec 04, 2025

Why Theriva Biologics Inc. stock gets analyst attention2025 Institutional Moves & Weekly Top Performers Watchlists - Newser

Dec 04, 2025

How Theriva Biologics Inc. (SFY0) stock reacts to Fed tightening2025 Market Overview & Smart Investment Allocation Insights - Newser

Dec 04, 2025

Will Theriva Biologics Inc. stock outperform foreign stocksTake Profit & Daily Profit Focused Stock Screening - Newser

Dec 04, 2025

Will Theriva Biologics Inc. stock maintain strong growthQuarterly Earnings Summary & Fast Gain Stock Trading Tips - Newser

Dec 04, 2025

Can Theriva Biologics Inc. stock reach $200 price targetJuly 2025 Fed Impact & AI Optimized Trading Strategy Guides - Newser

Dec 04, 2025

Will Theriva Biologics Inc. stock beat value stocksMarket Movers & Growth Focused Stock Pick Reports - Newser

Dec 04, 2025

Dec 03, 2025

Theriva Biologics (NYSE: TOVX) files resale for 16,184,560 warrant shares - Stock Titan

Dec 03, 2025

Can Theriva Biologics Inc. stock deliver consistent EPS growthPortfolio Return Report & Low Drawdown Trading Techniques - Newser

Dec 03, 2025

Dec 02, 2025

Will Theriva Biologics Inc. stock top growth indexesTrade Exit Summary & Safe Entry Zone Identification - Newser

Dec 02, 2025

Will Theriva Biologics Inc. stock outperform benchmarks2025 Market Overview & Weekly High Return Opportunities - Newser

Dec 02, 2025

How Theriva Biologics Inc. stock reacts to monetary easingJuly 2025 Market Mood & AI Forecasted Stock Moves - Newser

Dec 02, 2025

Dec 01, 2025

Risks Report: Will Theriva Biologics Inc SFY0 stock draw ESG focused fundsWeekly Trade Recap & Accurate Entry and Exit Point Alerts - BỘ NỘI VỤ

Dec 01, 2025

Healthy Upside Potential: Theriva Biologics Inc (TOVX) - Setenews

Dec 01, 2025

Nov 28, 2025

Why Theriva Biologics Inc. stock appeals to dividend investors2025 Market WrapUp & Reliable Volume Spike Alerts - moha.gov.vn

Nov 28, 2025

Is Theriva Biologics Inc. stock supported by strong fundamentals2025 Volume Leaders & Weekly High Return Stock Forecasts - moha.gov.vn

Nov 28, 2025

Nov 27, 2025

EPS Watch: Why Theriva Biologics Inc. stock appeals to dividend investorsJuly 2025 News Drivers & Growth Focused Entry Point Reports - BỘ NỘI VỤ

Nov 27, 2025

What market sentiment indicators show for Theriva Biologics Inc. (SFY0) stockEarnings Growth Report & Technical Confirmation Alerts - moha.gov.vn

Nov 27, 2025

Nov 26, 2025